Shares of Gilead Sciences Inc. slipped 4.28% to $109.64 Friday, on what proved to be an all-around dismal trading session for ...

What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

This was the stock's second consecutive day of gains.

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.